13F-HR: Regeneron Pharmaceuticals Discloses Q2 2025 Equity Holdings

Regeneron Pharmaceuticals, Inc. has filed its Form 13F-HR, revealing its equity holdings totaling over $1.48 billion across four biotechnology and pharmaceutical companies as of June 30, 2025.

Summary

• Regeneron Pharmaceuticals, Inc. filed its Form 13F-HR for the quarter ended June 30, 2025.
• The report details equity holdings with a total value of $1,485,002,709.
• The portfolio consists of four distinct holdings.
• Key holdings include Alnylam Pharmaceuticals, Inc. (valued at $1,449,289,070 with 4,444,445 shares), Intellia Therapeutics, Inc. (valued at $34,734,093 with 3,702,995 shares), Adicet Bio, Inc. (valued at $590,592 with 968,183 shares), and Adverum Biotechnologies, Inc. (valued at $388,954 with 180,909 shares).
• All reported holdings are under sole investment discretion.

Sentiment

Score: 5

Explanation: The filing is a standard regulatory disclosure of equity holdings and does not inherently convey positive or negative sentiment regarding Regeneron's operational performance or future prospects. It simply provides a snapshot of their investment portfolio.

Positives

• Maintained significant equity investments in the biotechnology and pharmaceutical sectors, reflecting continued strategic interest.
• A substantial portion of the portfolio is concentrated in Alnylam Pharmaceuticals, Inc., indicating a strong conviction in that specific company.

Negatives

• Context on the performance of these holdings or any changes from previous periods is not provided, making it difficult to assess negative implications solely from this report.
• The relatively small number of holdings (four) could indicate a concentrated portfolio, which may carry higher risk if any of the individual investments perform poorly.

Risks

• Risks associated with the investments or Regeneron's operations are not explicitly detailed.
• Investment in biotechnology companies inherently carries risks related to drug development, clinical trial outcomes, regulatory approvals, and market adoption.
• Concentration risk exists due to the significant allocation to a single holding, Alnylam Pharmaceuticals, Inc.

Future Outlook

The Form 13F-HR is a historical disclosure of equity holdings and does not contain forward-looking statements or guidance regarding future investment strategies or company performance.

Management Comments

• Leonard Brooks, Senior Vice President, Treasurer, signed the report on behalf of Regeneron Pharmaceuticals, Inc.
• The signatory represents that the information contained in the report is true, correct, and complete.

Industry Context

Regeneron Pharmaceuticals, a leading biotechnology company, maintains strategic investments primarily within the biotechnology and pharmaceutical sectors. The disclosed holdings in companies like Alnylam Pharmaceuticals and Intellia Therapeutics align with broader industry trends focusing on advanced therapeutic modalities such as RNA interference and gene editing, which are areas of significant innovation and growth within the biopharmaceutical landscape.

Comparison to Industry Standards

• The disclosed holdings reflect a concentrated investment strategy, with a substantial portion allocated to Alnylam Pharmaceuticals, Inc., a leader in RNAi therapeutics.
• This concentration is not uncommon for strategic investors who may seek to deepen their involvement or gain exposure to specific technological platforms.
• Regeneron's investment in companies like Intellia Therapeutics, a prominent CRISPR gene editing company, positions its portfolio within the cutting-edge areas of biotech research, similar to other large pharmaceutical companies that invest in or partner with innovative smaller biotech firms.

Stakeholder Impact

• Shareholders: Provides transparency into Regeneron's investment portfolio and strategic allocation of capital, which can inform investment decisions.
• Investment Professionals: Offers insights into Regeneron's investment strategy and conviction in specific biotech companies.

Next Steps

• No future actions, events, or milestones related to the disclosed holdings or Regeneron's broader investment strategy are specified.

Key Dates

Keywords

Regeneron Pharmaceuticals, 13F, SEC filing, equity holdings, institutional investment, biotechnology, pharmaceuticals, Alnylam Pharmaceuticals, Intellia Therapeutics, Adicet Bio, Adverum Biotechnologies, investment portfolio